Work

54O Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC)

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.189

Authors: V.Y.M. Heong, F. Marmé, H.S. Rugo, S.M. Tolaney, A. Bardia, P. Schmid, W. Verret, T. Valdez, H. Wang, J. Cortes

Institutions: Tan Tock Seng Hospital, National Healthcare Group, University Medical Centre Mannheim, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Harvard University, Massachusetts General Hospital, Queen Mary University of London, Cancer Research UK, Gilead Sciences (United States), MedSIR (Spain)

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, Gilead Sciences, Astex Pharmaceuticals

OpenAlex ID: W4389279839

FWCI: 0.529

Cites:

Cited by: 2

Related to: 10